CarolynYungHoMD
Cardiology • Boston, MAEchocardiography, Cardiovascular Disease Genetics
Associate Professor of Medicine, Brigham and Women's Hospital
Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Pbb 3
Boston, MA 02115Phone+1 617-732-7317
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1998 - 2001
Harvard Medical SchoolClass of 1995
Certifications & Licensure
MA State Medical License 2000 - 2026- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Start of enrollment: 2006 Jan 01
- Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM Start of enrollment: 2014 Mar 01
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 445 citationsMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri
Lancet. 2020-09-12 - 95 citationsMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlle...John A. Spertus, Jennifer T. Fine, Perry M. Elliott, Carolyn Y. Ho, Iacopo Olivotto
Lancet. 2021-06-26 - 360 citationsGenotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)Carolyn Y. Ho, Sharlene M. Day, Euan A. Ashley, Michelle Michels, Alexandre C. Pereira
Circulation. 2018-10-02
Lectures
- Circulating microRNAs as a Biomarker of Pediatric Hypertrophic Cardiomyopathy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- The Future of HCM: new Diagnostic Tools and New Therapies2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyHarvard Medical School ,Department Of Continuing Education, Boston, Massachusetts - 10/13/2012
Authored Content
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
- Evaluation of Mavacamten in Symptomatic Patients with Nonobstructive Hypertrophic CardiomyopathyJune 2020
Press Mentions
Is Heart Disease Genetic?January 15th, 2021
MAVERICK-HCM: Mavacamten Well Tolerated in Patients with Nonobstructive HCMMarch 30th, 2020
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy PatientsMarch 30th, 2020- Join now to see all
Grant Support
- Using Genetics For Early Phenotyping &Prevention Of Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2010–2011
- Diagnostic And Treatment Strategies For Preclinical HCMNational Heart, Lung, And Blood Institute2005–2009
- Diastolic Function In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2002–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
